Pharmacoscopy® interrogates drug action in primary human tissues with automated high content microscopy and AI-powered single cell image analysis.
Pharmacoscopy® can provide unique patient-relevant insights into the preclinical activity of drug molecules to ultimately enhance the chances of success in clinical development. Applications include:
Pharmacoscopy® can select fully individualised cancer treatments based on ex vivo drug activity measured in a patient's tumour tissue to enhance response and progression free survival.
Pharmacoscopy® is the first-ever functional precision oncology platform that has demonstrated the ability to prioritise highly effective drugs in a prospective clinical study.
In the EXALT I landmark study, patients were treated with drugs selected with Allcyte's AI powered single cell screening technology.
54% of patients responded and experienced a significantly longer progression free survival compared to the prior line of therapy (Snijder et al. 2017, Lancet Hematology and Staber et al. 2020 ASH 2020).
Pharmacoscopy® works with unprecedented single cell resolution to understand on- versus off-target drug effects even in highly complex tissues. Our clinical studies have demonstrated that single cell resolution is essential to measure a clinically translatable drug response.
Pharmacoscopy® works with liquid and solid tissues, 2D and 3D assay formats enabled by innovative AI-powered image analysis.
With Pharmacoscopy® you can profile libraries of >100 molecules or combination matrices even in limited tissues. Competing platforms typically are limited to single to a few 10s of drugs.
Pharmacoscopy® is optimised for high reproducibility and well-documented performance through extensive analytical assay validation.